Phase II Trial Evaluating the Safety and Efficacy of Atezolizumab in Combination With Cabozantinib for the Treatment of Metastatic, Refractory Pancreatic Cancer
Latest Information Update: 25 May 2024
At a glance
- Drugs Atezolizumab (Primary) ; Cabozantinib (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 08 Apr 2024 Planned End Date changed from 1 Mar 2024 to 1 Mar 2025.
- 08 Apr 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Mar 2025.
- 04 Apr 2023 Planned End Date changed from 1 Mar 2023 to 1 Mar 2024.